Cystatin SN promotes epithelial-mesenchymal transition and serves as a prognostic biomarker in lung adenocarcinoma

Background Cystatins are a class of proteins that can inhibit cysteine protease and are widely distributed in human bodily fluids and secretions. Cystatin SN (CST1), a member of the CST superfamily, is abnormally expressed in a variety of tumors. However, its effect on the occurrence and development of lung adenocarcinoma (LUAD) remains unclear. Methods We obtained transcriptome analysis data of CST1 from The Cancer Genome Atlas (TCGA) and GSE31210 databases. The association of CST1 expression with prognosis, gene mutations and tumor immune microenvironment was analyzed using public databases. Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) were performed to investigate the potential mechanisms of CST1. Results In this study, we found that CST1 was highly expressed in lung adenocarcinoma and was associated with prognosis and tumor immune microenvironment. Genetic mutations of CST1 were shown to be related to disease-free survival (DFS) by using the c-BioPortal tool. Potential proteins binding to CST1 were identified by constructing a protein-protein interaction (PPI) network. Gene set enrichment analysis (GSEA) of CST1 revealed that CST1 was notably enriched in epithelial-mesenchymal transition (EMT). Cell experiments confirmed that overexpression of CST1 promoted lung adenocarcinoma cells migration and invasion, while knockdown of CST1 significantly inhibited lung adenocarcinoma cells migration and invasion. Conclusions Our comprehensive bioinformatics analyses revealed that CST1 may be a novel prognostic biomarker in LUAD. Experiments confirmed that CST1 promotes epithelial-mesenchymal transition in LUAD cells. These findings will help to better understand the distinct role of CST1 in LUAD. Supplementary Information The online version contains supplementary material available at 10.1186/s12885-022-09685-z.

peptidase families C1 and C13 [3]. Interestingly, a growing number of experimental and clinical studies suggest that cystatin superfamily can affect all stages of cancer progression, including tumor growth, apoptosis, invasion, metastasis and angiogenesis [4]. There are four main inhibitory families in the cystatin superfamily, including the type I cystatins (Stefin family), type II cystatins (Cystatin family), type III cystatins (Kininogens family) and the type IV cystatins (Phytocystatin family) [5]. In these categories, Type II cystatins are the most investigated cystatins in cancer progression. Type II cystatins include a large number of homologous cysteine protease inhibitors which contain at least one cystatin domain [3]. Notably, S-type Cystatins (CST1, CST2, CST4), as members of Type II Cystatins, are proteins with unique roles, unlike other members. Existing studies suggest that they may play a role in promoting tumor progression [6,7]. In particular, the role of CST1 in cancers is receiving increasing attention [8,9]. CST1 mRNA contains three exons and two introns and it is translated into a protein containing 121 amino acid residues. Many studies have concluded that CST1 plays an important role in inflammation, tumorigenesis and tumor metastasis. For instance, in hepatocellular carcinoma, upregulation of cystatin SN promotes tumor progression and is predictive of a poor prognosis [10]. Moreover, Da-nian Dai et al. found that elevated CST1 expression promotes breast cancer progression [8]. In colorectal cancer, cystatin SN inhibits auranofininduced cell death by autophagy and ROS regulation via its glutathione reductase activity [11]. Silencing cystatin SN abrogates cancer progression and stem cell properties in papillary thyroid carcinoma [12]. Furthermore, CST1 promotes gastric cancer migration and invasion by activating the Wnt pathway [13]. However, the roles and mechanisms of CST1 in LUAD have not been clarified. Non-small-cell lung cancer (NSCLC), the leading cause of human death worldwide, mainly includes adenocarcinoma, squamous cell carcinoma (LUSC) and large cell carcinoma [14]. Among them, LUAD is the most common clinical subtype of NSCLC, which is highly heterogeneous and aggressive [15]. At present, metastasis is still the leading cause of death in cancer patients, and approximately 90% of cancer deaths are caused by metastasis [16]. Epithelial-to-mesenchymal transition is a key event in the transformation of early tumors into advanced malignant tumors and is closely related to the invasion and metastasis of tumor cells [17]. In this research, we comprehensively explored the expression, prognostic value and mutation characteristics of CST1 in LUAD. By constructing PPI networks of CST1 and its co-expressed genes, the function of CST1 was probed. In addition, we evaluated the potential association of CST1 with EMT in LUAD through functional analysis and experimental verification.

GEPIA
The GEPIA database is a newly developed web-based online tool [21]. (http:// gepia. cancer-pku. cn/) GEPIA can provide critical interaction and customization functions, such as differential expression analysis of tumor and normal RNAs, mapping based on cancer types or different pathological stages, patient survival analysis, correlation analysis, dimensional reduction analysis, and similar genetic testing based on data from the GTEx project and TCGA.

The cBioPortal
The cBioPortal for cancer genomics is an open online resource for the interactive exploration of a wide range of cancer genomics databases. The cBioPortal significantly reduces access barriers between complex genomic data and cancer researchers, facilitating rapid, intuitive, and high-quality access to molecular profiles and the clinical prognostic relevance of large-scale cancer genomics projects [22]. We selected 12 LUAD datasets for further analysis. (https:// www. cbiop ortal. org/).

Kaplan-Meier Plotter database
We analyzed the prognostic value of CST1 in lung cancer using Kaplan-Meier Plotter (https:// kmplot. com/ analy sis/), an online database of gene expression and survival data from 1925 clinical lung cancer patients (719 LUAD patients) [23]. Patient samples were divided into two groups (high and low expression) based on median expression to analyze the overall survival (OS) and first progression survival (FP) with HRs with 95% CIs and Log-rank p values.

PrognoScan database
The correlation between CST1 expression and prognostic parameters, such as OS and relapse-free survival (RFS) rates, can be investigated using PrognoScan in a large open cancer microarray dataset [24]. Hazard ratios with 95% confidence intervals were calculated. The database threshold was a Cox P value< 0.05. (http:// dna00. bio. kyute ch. ac. jp/ Progn oScan/ index. html).

GO and KEGG pathway enrichment analyses and GSEA
The biological function of CST1 in LUAD was assessed by GO and KEGG enrichment analyses [25]. Biological processes, cellular components and molecular functions relevant to CST1 were identified by GO, a mighty bioinformatics tool [26]. Potential mechanisms of CST1 were investigated using GSEA. GSEA can be used to determine whether a set of a priori defined genes differs significantly between two biological states. GO and KEGG analyses were performed using the R package Cluster-Profiler [27]. GSEA was performed using GSEA software 4.1.0.

Cell culture and specimens
BEAS2B, HBE and human LUAD cell lines (A549, H1299 and H1650) from the Cell Bank of the Chinese Academy of Sciences were cultured in RPMI 1640 medium (Shanghai Yuanpei Company) supplemented with 10% fetal bovine serum in a 5% CO2 humidified incubator at 37 °C [28]. A total of 31 LUAD tissues and corresponding paraneoplastic tissues were obtained from patients that provided informed consent at the First Affiliated Hospital of Soochow University (Suzhou, China). These specimens were immediately stored at − 80 °C until further processed. This work was authorized by the Ethics Committee of Soochow University.

Western blot assessment
Cells were hydrolyzed in RIPA buffer with a mixture of protease inhibitors and phosphatase inhibitors. Protein products were isolated by SDS-PAGE and transferred onto nitrocellulose membranes. We cut the membranes according to the molecular weight of the target proteins. The membranes were then blocked in TBST buffer with 3.0% BSA for 1 hour and incubated at 4 °C with primary antibodies overnight. The membranes were rinsed three times with TBST buffer and incubated at room temperature for 2 hours with the corresponding secondary antibody. Protein detection was performed using an enhanced chemiluminescence system. The expression of proteins of interest was normalized to that of β-actin. The following primary antibodies used in WB analysis: anti-mouse snail, anti-mouse Vimentin, anti-mouse E-cadherin, and anti-mouse N-cadherin (Cell Signaling Technology, Danvers, MA, USA); anti-rabbit CST1, antimouse GAPDH, and anti-mouse β-actin (ABclonal, Biotechnology Co. Ltd. Wuhan, China); and anti-rabbit or anti-mouse secondary antibodies (Beyotime Biotechnology Co. Ltd. Shanghai, China). Relative protein expression was normalized to that of β-actin. The same set of lysate samples were run in parallel (sister) gels to test different proteins (same for all figures).

RNA extraction and qRT-PCR assays
Total RNA was extracted using a standard TRIzol RNA extraction protocol [29]. Synthesis of cDNA with reverse transcriptase was conducted using the BeyoRT ™ II First Strand cDNA Synthesis Kit. The expression of CST1 mRNA was detected using qRT-PCR. The expression of CST1 was normalized to that of GAPDH. Relative mRNA levels were calculated using the ΔΔCt method [30]. Gene expression levels were calculated relative to that of GAPDH. The following primers were used: CST1 (Forward Primer: GGG TGG CAT CTA TAA CGC AG; Reverse Primer: CTG TTG CCT GGC TCT TAG T); GAPDH (Forward Primer: TGA CTT CAA CAG CGA CAC CA; Reverse Primer: CAC CCT GTT GCT GTA GCC AAA).

Wound-healing migration assay
A549 cells and H1299 cells were inoculated and cultured in 6-well plates until they reached 95% confluence. The cells were then scraped with the tip of a sterilized straw and cultured in serum-free media for 24 hours [32]. The cells were photographed under a microscope in five random areas. ImageJ Launcher software was used to analyze the distances of cell migration to scratched areas. Each wound healing experiment was repeated in triplicate.

Transwell assays
Transwell panels were used for the Transwell test (BD Biosciences). Briefly, A549 cells or H1299 cells with 1% FBS medium were added in each upper chamber and 20% FBS medium was placed as chemoattractant in each lower chamber. The chamber was removed after 24 hours of incubation in a 37 °C incubator, and the upper surface was cleaned with swabs. The cells invading the lower layer were stained with 1% crystalline violet. Cells from three microscope images were photographed and counted [33]. The results were affirmed through three repeat trials.

Immunofluorescence
For immunofluorescence assay, cells seeded on coverslips which were washed with 1 × PBS and fixed with 4% PFA for 20 minutes. Then cells were permeabilized with 0.5%Triton X-100 and blocked with 5% BSA for 30 minutes. After three washes with 1 × PBS, the cells were incubated with the first antibodies at 4 °C overnight and then followed by one-hour staining with fluorescent secondary antibodies (Abcam, USA) and counterstained with DAPI [34].

CST1 expression is increased in LUAD patients and associated with clinical parameters
The flow diagram of our present study is illustrated in Fig. 1. CST1 is generally highly expressed in the TCGA-GTEx pan-cancer database (Fig. 2a), indicating that CST1 may function as an oncogene in cancers. We used the TCGA database (Fig. 2b, c), GSE31210 (Fig. 2d) and GEPIA database (Fig. 2e) to analyze the expression level of CST1 in LUAD and found that CST1 was significantly over-expressed in tumors. Then, we used the TCGA database to analyze the expression of CST1 at different pathological and TNM stages, suggesting that CST1 is associated with clinical parameters (Fig. 2f-i). In addition, the expression differences of CST1 in different gender and age were compared. We found that the expression levels of CST1 in female patients were slightly higher than that in male patients, but there was no statistical difference in age ( Fig. 2j-k). To verify the database results, 31 pairs of paracancerous and cancerous tissues were subjected to qRT-PCR analysis, and CST1 expressions were found to be higher in cancer tissues (Fig. 3a). The representative WB results of 6 pairs of tissue specimens were shown in Fig. 3b. In addition, we verified this finding in the HBE, BEAS2B, H1650, A549, and H1299 cell lines (Fig. 3c, d). Among them, HBE and BEAS2B cells were primary control cells while H1650, A549 and H1299 cells were lung adenocarcinoma cells. The results showed CST1 was dramatically overexpressed in LUAD cells, especially A549 and H1299 cell lines, paving the way for their selection for further experimental verification. Furthermore, we investigated the cellular localization of CST1 in BEAS2B, A549 and H1299 cells. Immunofluorescence results revealed that CST1 was primarily located in the cytoplasm of normal lung epithelial cells and lung adenocarcinoma cells, and the staining pattern was vesicular. In addition, CST1 was strongly expressed in A549 and H1299 cells, but less in BEAS2B cells (Fig. 3e).

Increased CST1 expression correlates with poor prognosis in LUAD patients
We used the Kaplan-Meier Plotter database to carry out survival analysis based on the overall survival (OS) (Fig. 4a, b) and first progression survival (FP) (Fig. 4d, e) of LUAD and LUSC patients, respectively. We found that for the OS and FP of LUAD patients, high expression of CST1 was correlated with poor prognosis (P < 0.05). However, the results were not statistically significant in LUSC. To confirm this result, survival analysis was performed with the GSE31210 (LUAD) database (Fig. 4c, f ), and high expression of CST1 was correlated with poor prognosis in terms of OS and relapse-free survival (RFS) (P < 0.05).

Prognostic value of CST1 based on various clinicopathologic features
To better comprehend the prognostic value and possible mechanism of CST1 in LUAD, Kaplan-Meier Plotter was used to analyze the expression levels of CST1 and impacts of each factor on prognosis of OS and FP in LUAD. The stage 1 and only surgical margin negativity parameters were correlated with poor OS in LUAD (Fig. 4g). Regarding the FP of LUAD patients, the parameters stage 1, AJCC stage T1, AJCC stage N1, female sex, nonsmoker, and only negative surgical margins were associated with poor prognosis (Fig. 4h). These results suggested that mRNA expression of CST1 had prognostic value for LUAD.

Genetic alteration and PPI network of CST1 in LUAD
The genetic mutation of CST1 in LUAD was analyzed by using the c-BioPortal online tool. We selected 4309 samples (lung adenocarcinoma) from 12 databases in the c-BioPortal (Fig. 5a). By analyzing these samples, we found an overall mutation rate of 2.3% for CST1, with DNA copy number amplification being the most common mutation pattern (Fig. 5c). In addition, we identified a total of 10 somatic mutation sites in CST1. Seven of the sites were mutated in a missense way, and three were mutated in a truncating way (Fig. 5b). Furthermore, we investigated the prognostic differences between patients in the mutant and non-mutant groups. Results showed no significant difference in overall survival, but in diseasefree survival, patients with mutations had significantly worse survival than those without mutations (Fig. 5d). These suggested that mutations in CST1 may influence tumor progression and, consequently, patients' outcome. Remarkably, we also used GeneMANIA and STRING databases to explore genes that potentially interact with CST1, and construct protein-protein interaction networks. GeneMANIA and STRING datasets displayed the top 30 interacting genes of CST1, respectively (Fig. 5e, f). The protein networks include seven types of connections: Physical Interactions, Co-expression, Predicted, Colocalization, Genetic Interactions, Pathway, Shared protein domains. Interestingly, we found a large number of CST superfamily members in the protein network, which suggested that CST1 may play a role in promoting tumor progression in combination with other members of the CST superfamily.

Tumor immune microenvironment of CST1 in LUAD
Lung adenocarcinoma has an extremely complex tumor immune microenvironment, which is closely associated with tumor progression and metastasis. Therefore, it is relevant to explore whether CST1 can contribute to tumor progression by affecting the tumor microenvironment. We analyzed the tumor immune microenvironment of CST1 by using the GSE31210 database. Based on the gene expression profile, immune infiltrating cells scores were calculated for each sample using the MCP-Counter algorithm via the R package IOBR. As shown in Fig. 6a, b, the infiltration levels of Fibroblasts, NK cells, Neutrophils, and Endothelial cells were significantly different between the high and low CST1 expression groups. Tumor-associated fibroblasts (CAFs) were more abundant in the CST1 high expressed group, whereas endothelial cells, neutrophils, and NK cells were less abundant in the CST1 high expressed group. In addition, we used the Pearson analysis to investigate the correlation between CST1 and infiltration abundance of these 10 cell types. Notably, we found that CST1 expression levels were positively correlated with Fibroblasts, while negatively correlated with NK cells, Neutrophils, and Endothelial cells (Fig. 6c). These results suggested that CST1 may play a pro-tumor role by affecting the immune and stromal microenvironments.

GO and KEGG analyses of genes co-expressed with CST1 in LUAD
We used the Linkdomics database to identify genes coexpressed with CST1 in LUAD. The gene denoted by the red dot was positively associated with CST1, while that denoted by the green dot was negatively associated with CST1 (P < 0.01) (Fig. 7a). The top 50 genes positively and negatively correlated with CST1 are listed in Fig. 7b and c, respectively. Subsequently, GO (Additional file 1: Table S1) and KEGG enrichment analyses of the top 500 genes that were positively correlated with CST1 expression in the TCGA database were performed (Additional file 2: Table S2). Figure 7d showed the enrichment analysis of the top 20 biological processes, and the results revealed that CST1 is mainly related to extracellular structure organization, extracellular matrix organization, ossification, epithelial cell proliferation, leukocyte migration, and regulation of the Wnt signaling pathway. Figure 7e showed the accumulation analysis of the top 20 cellular components, and the results revealed that CST1 is mainly associated with collagen-containing extracellular matrix, the endoplasmic reticulum lumen, cell-substrate junctions, focal adhesion and adherens junctions. Figure 7f showed the enrichment analysis of the top 20 molecular functions, and the results revealed that CST1 is mainly related to extracellular matrix structural constituents, receptor ligand activity, cell adhesion molecule binding, glycosaminoglycan binding, and endopeptidase activity. Then, we performed KEGG enrichment analysis of CST1, and the results revealed that CST1 is mainly related to EMT (Fig. 7g). For example, the PI3K-Akt signaling, focal adhesion, Wnt signaling, ECM-receptor interaction, tight junction, and TGF-beta signaling pathways were identified. Furthermore, the KEGG visual network of CST1 was constructed and shown in Fig. 7h.

CST1 was enriched for EMT in LUAD as determined by GSEA
The molecular mechanisms of CST1 in LUAD patients were further investigated by GSEA. According to the CST1 median expression level, the gene expression data were divided into high and low expression groups, and the gene sets were arranged 1000 times for each analysis. Throughout this process, we considered the expression level of CST1 to be the phenotype. Phenotypic enrichment pathways were classified according to the p.adjust values and normalized enrichment scores (NESs). We chose the hallmark pathway, and the GSEA results showed that multiple gene sets were enriched in LUAD, including those related to epithelial-mesenchymal transition, the P53 pathway, coagulation, NOTCH signaling, apical junctions, myogenesis, apoptosis, angiogenesis, and IL2_STAT5 signaling (Additional file 3: Table S3).  These results strongly indicated the involvement of CST1 in the regulation of EMT in LUAD (Fig. 7i, j).

Overexpression of CST1 promotes LUAD cell migration and invasion
We overexpressed CST1 in A549 and H1299 cells and then detected the mRNA levels of CST1 using qRT-PCR (Fig. 8a, d). The protein level of CST1 was detected by western blot (Fig. 8b, e). EMT-associated markers in cell lines overexpressing CST1 were measured, revealing increased levels of N-cadherin, Vimentin and Snail and a decreased level of E-cadherin (Fig. 8c, f ). The migration capacity of CST1-overexpressing cell lines was determined by the scratch method, revealing the enhanced migration of A549 and H1299 cells overexpressing CST1 compared to the vector control cell lines (Fig. 8g, h). The Transwell results revealed that the migration and invasion abilities of the above-mentioned cell lines were also enhanced (Fig. 8i, j).

Knockdown of CST1 inhibits LUAD cell migration and invasion
Moreover, we constructed A549 and H1299 cell lines with CST1 silencing. Real-time fluorescence quantification (Fig. 9a, d) and western blot (Fig. 9b, e) were utilized to detect the expression level of CST1 in the silenced cells.
The results showed that CST1 was successfully knocked down. EMT-associated markers were detected in CSTsilenced A549 and H1299 cell lines, revealing decreased levels of N-cadherin and Vimentin and an increased level of E-cadherin (Fig. 9c, f ). We used the scratch assay to verify that the migration capacities of si-CST1-1 and si-CST1-2 cells were decreased compared with that of si-NC cells (Fig. 9g, h). Transwell experiments verified the decreased migration and invasion abilities of the CST1-silenced A549 and H1299 cell lines (Fig. 9i, j).

Discussion
Lung adenocarcinoma is a highly heterogeneous and aggressive disease with extremely high morbidity and mortality. Therefore, finding valuable biomarkers for the prognostic assessment of lung adenocarcinoma plays an important role in lung adenocarcinoma therapy [35].
Recently, CST1 has received increased research attention as a member of the cystatin family of cysteine protease inhibitors [36]. However, the mechanisms of its aberrant expression in cancer and its biological behavior in cancer remain unclear. By comprehensively assessing the expression, clinicopathological significance, prognostic value, and functional impact of CST1 in LUAD, we found that CST1 is expressed at extremely high levels in LUAD patients and associated with poor prognosis. We revealed that CST1 is capable of promoting EMT, migration and invasion in LUAD, providing a solid basis for further downstream pathway studies. CST1 has been shown to be highly expressed in a wide range of cancers, including gastric [37], breast [38], colon [9], thyroid [39], liver [10], and esophageal [40] cancers, and shown to be related to poor prognosis [39]. However, its role in LUAD has rarely been reported. In this study, we analyzed CST1 expression and prognostic information regarding LUAD using public databases such as TCGA-GTEx, TCGA, and GSE31210 and further validated that CST1 expression was notably higher in LUAD tissues than in paracancerous tissues. During cancer development [41], uncontrolled regulation of complex molecular networks often leads to abnormal gene expression [42]. Previous studies have shown that CST1 is strongly associated with the progression and aggressive metastasis of malignant tumors [43]. Although its role varies, CST1 contributes to hyperplasia, invasion, and metastasis in most malignancies. For example, Kim JT et al. identified CST1 and CST3 as having a 50% homologous binding domain [44]. CST1 can competitively bind CST3 with cathepsin B, and CST1-CST3 complexes have a higher affinity than CST3-cathepsin B complexes. This effect can counteract the inhibition of cathepsin B by CST3, thereby restoring the activity of cathepsin B in cells and promoting tumor progression. Yanfang Liu et al. found that CST1, as an oncogene in ER+ breast cancer, is involved in ER+ breast cancer progression by regulating the ERα/PI3K/AKT/ERα loop pathway [38]. Nevertheless, the function of CST1 in LUAD progression and malignant metastasis is unclear. A retrospective analysis of 174 cases of non-small-cell lung cancer was conducted separately by experts from Sun Yat-sen University [45]. In that study, they mapped the risk ratio of recurrence and metastasis in patients with LUAD and found a significant difference between the high and low CST1 expression groups. (P < 0.004) Moreover, differential expression of CST1 has prognostic significance. (P = 0.004).
In this study, we identified significant high expression of CST1, a member of the CST superfamily, in lung adenocarcinoma based on expression profiling from TCGA and GEO databases. Our results were validated by qRT-PCR and WB assays in lung adenocarcinoma samples and cell lines. Further, we found that the expression level of CST1 was correlated with clinicopathological features. By using prognostic analysis of Kaplan-Meier Plotterr and PrognoScan database, we found that high expression of CST1 was associated with poor prognosis in lung adenocarcinoma patients. These results suggested that CST1 may act as a pro-oncogene affecting tumor progression. Based on mutation analysis of CST1, we explored that DNA copy number alteration was the most common form of mutation. Patients with CST1 mutations had significantly worse disease-free survival, suggesting that increased frequency of CST1 mutations may contribute to tumor progression. In addition, through the PPI network constructed using the GeneMANIA and STRING databases, we speculated that the CST superfamily may play a synergistic role in co-acting as cancer promoters.
Notably, the role of the CST superfamily in the tumor immune microenvironment has previously been reported [46][47][48]. Therefore, this study also delved into the impact of CST1 on the tumor immune microenvironment. The components of the tumor microenvironment interact with tumor cells, affecting tumor growth, metastasis and drug resistance. By using the MCPCounter algorithm, we investigated the effect of CST1 on immune infiltration abundance in 10 cell types. Excitingly, we found a strong association between CST1 and cells in the tumor microenvironment. CST1 was positively associated with tumor-associated fibroblasts (CAFs). CAFs have previously been reported to play an important role in cancer [49,50]. CAFs promote tumor progression, invasion and metastasis by secreting multiple cytokines and metabolites that inhibit immune cell function [51]. In addition, CAFs shape the extracellular matrix, forming a barrier to drug and immune cell infiltration. Therefore, CST1induced infiltration of CAFs may inhibit immune cells capacity and further promote cancer. Remarkably, CST1 was negatively associated with neutrophils and endothelial cells. Neutrophils play a crucial role in inflammatory response and host defense against microbial infection. Recent studies have shown that neutrophils are thought to be part of an immune response that regulates tumor growth and metastasis and play a role in anti-tumor effects in humans [52]. Therefore, a decrease in neutrophils abundance due to CST1 may indirectly reduce neutrophils' tumor inhibition. In addition, researchers at the Max Planck Institute in Germany found that tumor cells kill specific endothelial cells in the walls of blood vessels [53]. This allowed tumor cells to pass through the endothelial cell barrier in the lung, leaving the blood vessels to build metastatic cancer. Therefore, whether CST1 promotes tumor metastasis by killing endothelial cells through a similar mechanism deserves further investigation. Apart from stromal cells, we also found a negative correlation between CST1 expression and NK cells. NK cells have a variety of functions that limit the growth and spread of cancer cells [54]. Upon entering the tumor's immune microenvironment, NK cells can kill cancer cells through a "loss of self " mechanism. Taken together, these analyses revealed that CST1 may alter the tumor microenvironment and play a role in suppressing antitumor immunity. Therefore, it is of practical significance to explore immunotherapy or targeted therapy targeting CST1.
To further investigate the biological function of CST1, we performed GO and KEGG enrichment analyses and found that CST1 is primarily involved in EMT-associated signaling pathways, such as the PI3K-Akt signaling, Wnt signaling, ECM-receptor interaction, and TGFbeta signaling pathways. To further verify the results of enrichment analysis, we performed GSEA analysis, which revealed a correlation between EMT and CST1. In view of the consistent results obtained by enrichment analysis, we hypothesized that CST1 may play an important role in lung adenocarcinoma metastasis and invasion. Therefore, we decided to use experiments to further validate the results of our bioinformatics analyses. Experiments validated that overexpression of CST1 promotes LUAD cell migration and invasion and while knockdown of CST1 inhibits LUAD cell migration and invasion. To sum up, although there are some limitations, the findings of this study provide exciting new clues that require further focused research to elucidate specific mechanisms.

Conclusions
In conclusion, our comprehensive bioinformatics analyses revealed that CST1 was associated with the prognosis and clinical characteristics of LUAD patients, and it may be a new prognostic biomarker. Functional enrichment analysis and experimental validation revealed that CST1 promotes epithelial-mesenchymal transition. This study Fig. 8 Overexpression of CST1 promotes EMT in A549 and H1299 cells. a, d The mRNA levels of CST1 in A549 and H1299 cells overexpressing CST1 were detected by q-PCR. b, e The protein levels of CST1 in A549 and H1299 cells overexpressing CST1 were detected by western blotting. c, f The expression of EMT markers was detected by western blotting. g, h Wound-healing migration assays of A549 and H1299 cells overexpressing CST1 as well as control cells, which were treated as described above. i-j A549 and H1299 cells overexpressing CST1 were allowed to migrate through an 8-μM-pore size transwell insert. Overexpression of CST1 inhibits the migration and invasion abilities of A549 and H1299 cells. Migrated and invaded cells were stained and counted in at least three microscopic fields. *p < 0.05, **p < 0.01 ***p < 0.001. (The blots were cutted prior to hybridisation with antibodies) Knockdown of CST1 inhibits EMT in A549 and H1299 cells. a, d The mRNA levels of CST1 in CST1-silenced A549 and H1299 cells were detected by q-PCR. b, e The protein levels of CST1 in CST1-silenced A549 and H1299 cells were detected by western blotting. c, f The expression of EMT markers was detected by western blotting. g, h Wound-healing migration assays of CST1-silenced A549 and H1299 cells as well as control cells, which were treated as described above. i-j CST1-silenced A549 and H1299 cells were allowed to migrate through an 8-μM-pore size Transwell insert. Knockdown of CST1 inhibited the migration and invasion abilities of A549 and H1299 cells. Migrated and invaded cells were stained and counted in at least three microscopic fields. *p < 0.05, **p < 0.01 ***p < 0.001. (The blots were cutted prior to hybridisation with antibodies)